Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New HIV treatment guidelines boost TAF and dolutegravir but warn about Trogarzo and advise against Cabenuva for pregnant people.
A study showed that as HIV treatment expanded, teens lost fewer parents to the virus.
Black and Latino men who have sex with men are not seeing the same improvements as white men, but innovative approaches can help.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
HIV stigma and worries about disclosure were also associated with lower odds of taking treatment as prescribed.
The long-acting injectable regimen suppressed HIV in more than 90% of study participants, including those with obesity.
These encouraging results do not apply, however, to people who remain undiagnosed.
Having trouble adhering to your medications? There are solutions to the problem.
People who started treatment on the same day as their HIV diagnosis achieved an undetectable viral load sooner.
The updates include new information on optimizing therapy, dealing with virological failure and managing opportunistic infections.
Right now, it typically takes six years after an HIV drug is approved to obtain data for pregnant people.
Pioneering HIV doctor Paul Volberding and veteran activist Gregg Gonsalves reflect on the legacy of AIDS and its implications for COVID-19.
The new numbers are encouraging but Black and Latino people continue to be disproportionately affected by HIV.
The COVID-19 pandemic has profoundly disrupted almost every aspect of the battle against HIV.
Stroke is the number one killer of Americans—and nearly twice as common in Black Americans—but the effect of viral load hasn’t been clea...
HIV treatment usually requires daily pills, but longer-acting regimens are gaining ground.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.